Radical Operation of Infected Aortofemoral Prosthesis using Fresh Arterial Allograft: Our Mid-term Experience

Česká verzia

Authors: P. Šebesta; P. Štádler; P. Šedivý; P. Zdráhal; K. El Samman; V. Jindrák ^*; M. Syrůček ^**
Authors place of work: Oddělení cévní chirurgie, Nemocnice Na Homolce, primář doc. MUDr. P. Štádler, Ph. D. ; Oddělení mikrobiologie, Nemocnice Na Homolce, primář MUDr. V. Jindrák ^*; Oddělení patologie, Nemocnice Na Homolce, primář MUDr. M. Syrůček ^**
Published in the journal: Rozhl. Chir., 2011, roč. 90, č. 1, s. 4-13.
Category: Monothematic special - Original

Summary

Introduction:
The mid-term experience with the use of the fresh arterial allografts in the treatment of aortic or aortofemoral prosthetic infection is presented.

Material and methods:
Between 2001–2010 24 patients (23 with the infected graft in aortic or aortofemoral position and one with a mycotic aneurysm of the aortic bifurcation) were operated with the use of the fresh arterial allograft. Male/female ratio was 15/9, average age 65.8 (36–81) years. The gastrointestinal comorbidities dominated this cohort. The total of 70 previous vascular operations (1–9; m. 2.9/patient) were performed with the median of 5.8 years between the first and the last procedure. Seven patients had sepsis (29.2%), aortoeneteric fistula occurred in three. Various technical modifications of the aortobifemoral (13), aortounifemoral (8) bypass, aortic and aortoiliac replacement (3) were performed including the sequential distal reconstructions. The arterial allograft was used within 8–48 hours following harvest (the median cold ischemic time of 20 hours) and all patients were given cyclosporine A perioperatively.

Results:
In-hospital mortality was 20.8% (5/24), twice caused by postoperative hemorrhage from either the aortic anastomosis or the graft necrosis. The remaining deaths were not related to the allograft itself. Two limbs, preoperatively ischemic, were amputated (8.3%). The median follow-up is 4.6 years (3 m.–8 yrs.). The three-years survival was 68.4% and the known causes of death had no relation to the allograft. The late occlusion of the graft limb occurred twice, stenoses within its course twice and three femoral anastomotic stenoses were disclosed. All were treated either surgically or by PTA/stent and the redo procedures’ rate has thus reached 20.5% in the mid-term follow-up interval. One graft has shown a slight diffuse dilatation since requiring but follow-up.

Conclusions:
Under the conditions of the ABO compatibility tolerance and ongoing postimplantation immunosuppression the shortly ischemic arterial graft helds its anatomic structure and function and within the hostile setting of the previous infection represents a valuable alternative of the surgical treatment of the vascular prosthetic infection in the aortofemoral position or of the mycotic aneurysm.

Key words:
vascular prosthetic infection – arterial allograft – immunosuppression

Zdroje

1. O‘Hara, P. J., Hertzer, N. R., Beven, E. G., Krajewski, L. P. Surgical management of infected abdominal aortic grafts: review of a 25-year experience. J. Vasc. Surg., 1986; 3: 725–731.

2. Špaček, M., Bělohlávek, O., Votrubová, J., et al. Diagnostics of „non-acute“ vascular prosthesis infection using 18-F-FDG PET/CT: our experience with 96 prostheses. Eur. J. Nucl. Med. Mol. Imaging, 2009; 36(5): 850–858.

3. Young, R. M., Cherry, K. J. Jr., Davis, P. M., et al. The results of in situ prosthetic replacement for infected aortic grafts. Am. J. Surg., 1999; 178(2): 136–140.

4. Yeager, R. A., Taylor, L. M. Jr, Moneta, G. L., et al. Improved results with conventional management of infrarenal aortic infection. J. Vasc. Surg., 1999; 30: 76–83.

5. Koshiko, S., Sasajima, T., Muraki, S., et al. Limitations in the use of rifampicin-gelatin grafts against virulent organisms. J. Vasc. Surg., 2002; 35: 779–785.

6. Staffa, R., Kříž, Z., Vlachovský, R., et al. Autogenní vena femoralis superficialis jako náhrada infikované aorto-iliako-femorální cévní protézy. Rozhl. Chir., 2010; 89(1): 39–44.

7. Szilagyi, D. E., Rodriguez, F. J., Smith, R. F., Elliott, J. P. Late fate of arterial allografts. Observations 6 to 15 years after implantation. Arch. Surg., 1970; 101: 721–733.

8. Štádler, P., Šebesta, P., Klika, T., et al. Alografty v cévní chirurgii. Rozhl. Chir., 2005; 84(7): 350–355.

9. Prager, M., Holzenbein, T., Aslim, E., et al. Fresh arterial homograft transplantation: a novel concept for critical limb ischaemia. Eur. J. Vasc. Endovasc. Surg., 2002; 24: 314–321.

10. Kieffer, E., Gomes, D., Chiche, L., et al. Allograft replacement for infrarenal aortic graft infection: early and late rsults in 179 patients. J. Vasc. Surg., 2004; 39: 1009–1017.

11. Zhou, W., Lin, P. H., Bush, R. L., et al. In situ reconstruction with cryopreserved arterial allografts for management of mycotic aneurysms or aortic prosthetic graft infections: a multi-institutional experience. Tex. Heart Inst. J., 2006; 33(1): 14–18.

12. Brown, K. E., Heyer, K., Rodriguez, H., et al. Arterial reconstruction with cryopreserved human allografts in the setting of infection: A single-center experience with midterm follow-up. J. Vasc. Surg., 2009; 49(3): 660–666.

13. Vardanian, A. J., Chau, A., Quinones-Baldrich, W., Lawrence, P. E. Arterial allograft allows in-line reconstruction of prosthetic graft infection with low recurrence rate and mortality. Am. Surg., 2009; 75(10): 1000–1003.

14. Esperón, A., Kamaid, E., Diamant, M., et al. Uruguayan experience with cryopreserved arterial homografts. Transplant. Proc., 2009; 41(8): 3500–3504.

15. Adamec, M., Tosenovsky, P., Janousek, L. Simultaneous surgical repair of abdominal aortic aneurysm using fresh arterial allograft and renal transplantation. Eur. J. Vasc. Endovasc. Surg., 2001; 21: 467–468.

16. Mirelli, M., Buzzi, M., Pasquinelli, G., et al. Fresh and cryopreserved arterial homografts: immunological and clinical results. Transplant. Proc., 2005; 37: 2688–2691.

17. Litzler, P. Y., Thomas, P., Danielou, E., et al. Bacterial resistance of refrigerated and cryopreserved aortic allografts in an experimental virulent infection model. J. Vasc. Surg., 2009; 29: 1090–1096.

18. Saito, A., Motomura, N., Kakimi, M., et al. Vascular allografts are resistant to methicillin-resistant Staphylococcus aureus through indoleamine 2,3-dioxygenase in a murine model. J. Thorac. Cardiovasc. Surg., 2008; 136(1): 156–167.

19. Camiade, C., Goldschmidt, P., Koskas, F. et al. Optimization of the resistance of arterial allografts to infection: comparative study with synthetic prostheses. Ann. Vasc. Surg., 2001; 15: 186–196.

20. Locati, P., Novali, C., Socrate, A. M., et al. The use of arterial allografts in aortic graft infections. A three years experience on eighteen patients. J. Cardiovasc. Surg., 1998; 39: 735–741.

21. Noel, A. A., Gloviczki, P., Cherry, K. J., et al. Abdominal aortic reconstruction in infected fields: early results of the United States cryopreserved aortic allograft registry. J. Vasc. Surg., 2002; 35: 847–852.

22. Chiesa, R., Astore, D., Piccolo, G., et al. Fresh and cryopreserved arterial homografts in the treatment of prosthetic graft infections: experience of the Italian collaborative vascular homograft group. Ann. Vasc. Surg., 1998; 12: 457–462.

23. Marois, Y., Wagner, E., Paris, E., et al. Comparison of healing in fresh and preserved arterial allografts in the dog. Ann. Vasc. Surg., 1999; 13: 130–140.

24. Moriyama, S., Utoh, J., Sun, L. B., et al. Antigenicity of cryopreserved arterial allografts: comparison with fresh and glutaraldehyde treated grafts. Am. Soc. Artif. Intern. Organs J., 2001; 47: 202–205.

25. Gabriel, M., Kostrzewa, A., Sobieska, M. Immunologic reaction following cryopreserved aortic allograft replacement for major vascular infection. Transplant. Proc., 2002; 34: 713–714.

26. Matia, I., Adamec, M., Varga, M., et al. Aortoiliac reconstruction with allograft and kidney transplantation as a one-stage procedure: long term results. Eur. J. Vasc. Endovasc. Surg., 2008; 35: 353–357.

27. Fahner, P., Idu, M. M., van Gulik, T. M., Legemate, D. A. Systematic review of preservation methods and clinical outcome of infrainguinal vascular allografts. J. Vasc. Surg., 2006; 44: 518–524.

28. Mirelli, M., Stella, A., Faggioli, G. L., et al. Immune rsponse following fresh arterial homograft replacement for aortoiliac graft infection. Eur. J. Vasc. Endovasc. Surg., 1999; 18: 424–429.

29. Azuma, N., Sasajima, T., Kubo, Y. Immunosuppression with FK506 in rat arterial allografts:fate of allogeneic endothelial cells. J. Vasc. Surg., 1999; 29(4): 694–702.

30. Albertini, J. N., Barral, X., Branchereau, A., et al. Long-term results of arterial allograft below-knee bypass grafts for limb salvage: a retrospective multicenter study. J. Vasc. Surg., 2000; 31: 426–435.

31. Magne, J. L., Farrah, I., Roux, J. J., et al. Below-knee bypass using fresh arterial allografts for limb salvage: early results. Ann. Vasc. Surg., 1997; 11: 237–241.

32. Matia, I., Adamec, M., Janousek, L., et al. Fresh arterial grafts and conduits for vascular reconstructions in transplanted patients. Eur. J. Vasc. Endovasc. Surg., 2006; 32: 549–556.

33. Dinis da Gama, D., Sarmiento, C., Vieira, T., do Carmo, G. The use of arterial allografts for vascular reconstruction in patients receiving immunosuppression for organ transplantation. J. Vasc. Surg., 1994; 20: 271–278.

34. Šebesta, P., Štádler, P., Šedivý, P., Bartík, K. The seven-yearęsecondary patency of a fresh arterial allograft in the femorocrural position in a heart transplant recipient: a case report. Ann. Vasc. Surg., 2010, Epub. 6/2010; v tisku.

35. Štádler, P., Slížová, D., Krs, O., et al. Microscopic study of vascular allografts. Cor. Vasa, 2005; 47(1): 10–13.